Botulinum toxin-A as a treatment option for refractory idiopathic trigeminal neuralgia of the ophthalmic branch: a case report and literature review.

Oral Surg Oral Med Oral Pathol Oral Radiol

Department of Oral Medicine and Pathology, School of Dentistry, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada. Electronic address:

Published: May 2024

AI Article Synopsis

  • * Treatment usually involves medications or surgery, but both come with risks and potential side effects, leading to a search for alternative options.
  • * A case study presents a 58-year-old male with refractory trigeminal neuralgia of the ophthalmic branch that was successfully treated with onabotulinum toxin type A, suggesting it could be a viable option before considering surgery.

Article Abstract

Trigeminal neuralgia is one of the most common neurological pains affecting the head and neck and is associated with severe, lancinating, electrical pain episodes. The maxillary and mandibular branches are usually affected. The ophthalmic branch is rarely involved and, when present, it requires a comprehensive workup to rule out major conditions. Pharmacotherapy and surgery are the most common treatment options for this condition. Systemic medications may pose a wide range of side effects and effectiveness may decrease over time while surgery has inherent complications. Injectable onabotulinum toxins have been utilized for various applications in medicine and dentistry. There is, however, limited data on their use for the management of refractory trigeminal neuralgia of the ophthalmic branch. We present the case of a 58-year-old male diagnosed with refractory idiopathic trigeminal neuralgia affecting the ophthalmic branch, which was unresponsive to standard care and successfully managed with onabotulinum toxin type A. This treatment should be considered in cases of refractory trigeminal neuralgia prior to surgery. We reviewed the relevant literature concerning the application of Onabotulinum toxin A for managing trigeminal neuralgia of the ophthalmic branch. This case report and review aim to enlighten the application of Onabotulinum toxin A for managing refractory trigeminal neuralgia of the ophthalmic branch. Our case report and review show that Onabotulinum toxin A could be used for managing TN of the ophthalmic branch.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.oooo.2024.02.024DOI Listing

Publication Analysis

Top Keywords

trigeminal neuralgia
28
ophthalmic branch
28
neuralgia ophthalmic
20
branch case
16
onabotulinum toxin
16
case report
12
refractory trigeminal
12
toxin managing
12
refractory idiopathic
8
idiopathic trigeminal
8

Similar Publications

Microvascular decompression is considered a first-line treatment in classical trigeminal neuralgia. Teflon is the material commonly used. The use of autologous muscle has been occasionally reported.

View Article and Find Full Text PDF

This case series aimed to assess the treatment outcomes of onabotulinum toxin A (BTX-A) in patients with refractory posttraumatic trigeminal neuropathic pain (PTNP) and to conduct a narrative review of the evidence for BTX-A in PTNP. Thirteen patients were treated with BTX-A infiltrations. Patient demographic and pain characteristics, BTX-A administration, and treatment outcomes were retrospectively analyzed.

View Article and Find Full Text PDF

Pain assessment in trigeminal neuralgia (TN) mouse models is essential for exploring its pathophysiology and developing effective analgesics. However, pain assessment methods for TN mouse models have not been widely studied, resulting in a critical gap in our understanding of TN. With the rapid advancement of deep learning, numerous pain assessment methods based on deep learning have emerged.

View Article and Find Full Text PDF

Background: Trigeminal neuralgia (TN) is a prevalent and debilitating craniofacial pain disorder characterized by severe, unilateral, shock-like pain. Standard treatments include anti-epileptic drugs and surgical interventions, but many patients experience limited relief or adverse effects. Non-invasive therapies, such as transcutaneous electrical nerve stimulation (TENS), have emerged as alternative options.

View Article and Find Full Text PDF

Objectives: To investigate the effect of diffusivity metrics of magnetic resonance diffusion tensor imaging (MR-DTI) in the assessment of treatment effects.

Methods: MR-DTI examination for trigeminal neuralgia (TN) patients and the diffusivity metrics of the trigeminal ganglion (TG) were analyzed. Before and after the percutaneous stereotactic radiofrequency rhizotomy (PSR) operation, the treatment effect was assessed using pain scores and MR-DTI.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!